Latest Articles

Publication Date
Novel Small Molecule Inhibitors Show Efficacy in Endometrial Cancer - Targeted Oncology

Novel Small Molecule Inhibitors Show Efficacy in Endometrial Cancer Targeted Oncology

Published: Jan. 11, 2026, 4:14 p.m.
Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data - Investing.com UK

Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data Investing.com UK

Published: Jan. 9, 2026, 2:25 p.m.
Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data - Investing.com

Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data Investing.com

Published: Jan. 9, 2026, 1:59 p.m.
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 - Sahm

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 …

Published: Jan. 9, 2026, 6:18 a.m.
The role of insulin-like growth factor binding proteins in TGF-β1-induced fibroblast-myofibroblast transition during endometriosis fibrosis.

Fibrosis is a defining feature of endometriosis (EMS). Our previous single-cell RNA sequencing (scRNA-seq) revealed myofibroblasts (MFBs) as the predominant cells in ectopic endometrium (ECE), mainly derived from fibroblast-to-myofibroblast transition …

Published: Jan. 9, 2026, midnight
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 - The Manila Times

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 …

Published: Jan. 8, 2026, 12:53 p.m.
Transcriptomic landscape of coexisting ovarian clear cell carcinoma and endometriosis: Insights into malignant transformation.

This study investigateted the malignant transformation of endometriosis (EMS) into ovarian clear cell carcinoma (OCCC) using spatial transcriptomics and single-cell RNA sequencing (scRNA-seq) integration. Tissues with coexisting EMS and OCCC …

Published: Jan. 7, 2026, midnight
[A targeted approach to cardiovascular risk in women: towards improved screening and prevention].

In women, cardiovascular risk is influenced by factors that differ from those in men, including hormonal status, obstetric complications, and specific conditions such as migraine, endometriosis, or chronic inflammatory diseases. …

Published: Jan. 6, 2026, midnight
Using Lenvatinib/Pembrolizumab for Endometrial Cancer in Clinical Practice - Targeted Oncology

Using Lenvatinib/Pembrolizumab for Endometrial Cancer in Clinical Practice Targeted Oncology

Published: Jan. 5, 2026, 1:27 p.m.
Real-World Results for Lenvatinib Plus Pembrolizumab in Endometrial Cancer - Targeted Oncology

Real-World Results for Lenvatinib Plus Pembrolizumab in Endometrial Cancer Targeted Oncology

Published: Jan. 5, 2026, 1:12 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!